MarketMoodz
Jefferies Upgrades Abivax to Buy After Strong Obefazimod Data
Jefferies analyst Faisal Khurshid upgraded Abivax (ABVX) to Buy from Hold after new obefazimod data for ulcerative colitis showed malignancy rates in line with expected UC patient levels and meaningful remission in a subset of prior non-responders. The firm raised its price target to $158 from $108, and the stock surged 39% on Tuesday as investors reassessed the risk profile.
Key Takeaways
- Jefferies upgrades ABVX to Buy and raises the price target to $158 from $108, implying roughly 18% upside to the prior close.
- New obefazimod data report malignancy rates within expected ranges for ulcerative colitis patients.
- More than one-third of initial non-responders achieved remission after about 10 months, signaling durable efficacy in a subset.
- ABVX shares jumped 39% on Tuesday; LSEG data show 10 of 12 analysts rate Abivax Buy or Strong Buy.
People Involved
- Faisal KhurshidJefferies analyst
Entities Involved
- Abivax (ABVX)French biotechnology company developing obefazimod
- JefferiesInvestment bank issuing the upgrade and new price target
- ObefazimodInvestigational drug candidate for ulcerative colitis
- LSEG (London Stock Exchange Group)Data provider reporting analyst coverage
MarketMoodz Analysis
Jefferies’ upgrade reframes Abivax from a safety-overhang story to one where efficacy and manageable safety drive positive reappraisal. A $158 price target and a 39% one-day stock surge show how sensitive biotech valuations are to trial readouts; the upgrade could attract fresh institutional interest and compress short interest, but it does not eliminate binary risk tied to further data or regulatory review. Investors should view the move as a sentiment catalyst rather than a de-risking event—valuation upside depends on follow-on readouts and commercial viability.
Context matters: Abivax was downgraded earlier this month after initial trial data flagged cancer cases that lacked clear explanation. The new dataset, which Jefferies says puts malignancy rates in line with expectations and shows remission in over a third of initial non-responders after ~10 months, directly addresses that overhang. Those efficacy signals, if confirmed in primary source data, strengthen a case for a standalone launch or partnership. That said, the underlying efficacy and safety claims were flagged in the source material at medium confidence; investors should cross-check the primary readout and watch for detailed safety tables and independent adjudication.
What to watch next: upcoming full data releases, regulatory feedback, and Abivax’s cash runway and financing plans. Jefferies notes cash and the catalyst path remain open questions—if management outlines a clear regulatory timeline or secures partnering options, the stock could sustain its re-rate; conversely, fresh safety concerns or disappointing confirmatory data would quickly reverse gains. With 10 of 12 analysts already positive per LSEG, market expectations are rising—expect continued volatility around each new disclosure.
Source: Original Article